LabCorp's at-home coronavirus testing kit authorized by FDA

coronavirus test tubes
LabCorp said it plans to make the test available with a prescription in the coming weeks, starting with front-line healthcare workers and first responders. (Getty/RossHelen)

The FDA has given the green light to its first at-home test for COVID-19, allowing people to collect nasal swab samples themselves and then ship them to a clinical laboratory to be analyzed for signs of the novel coronavirus.

SPECIAL REPORT: FierceMedTech's 2019 Fierce 15

Offered by LabCorp, the Pixel test is built off the coronavirus diagnostic that received an FDA authorization in early March, forming the basis of its nationwide testing service. The new home kit includes specifically designed swabs that only have to go as far as the nostril, as opposed to the deeper nasopharyngeal swabs used in previous tests.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Those swabs must reach farther back into the nose’s upper cavities to collect a clean sample—a difficult and uncomfortable procedure that requires a trained healthcare professional—which had been a hindrance to the development of home-based tests.

The kit also includes an ice pack, insulation and a FedEx box for overnight shipping. LabCorp said it plans to make the test available with a prescription in the coming weeks for $119, starting with front-line healthcare workers and first responders. Results will typically take one to two days.

RELATED: FDA clamps down on at-home coronavirus testing, citing fake products and bad actors

“The FDA’s around-the-clock work since this outbreak began has resulted in the authorization of more than 50 diagnostic tests and engagement with over 350 test developers,” FDA Commissioner Stephen Hahn said in a statement

“Specifically, for tests that include home sample collection, we worked with LabCorp to ensure the data demonstrated from at-home patient sample collection is as safe and accurate as sample collection at a doctor’s office, hospital or other testing site,” Hahn added.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.